Surrozen, Inc./DE Operating Lease, Payments
Surrozen, Inc./DE (SRZN) reported Operating Lease, Payments of $2.44 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-23
- Surrozen, Inc./DE operating lease, payments for fiscal 2025 was $2.44M, a 8.61% decline from fiscal 2024.
- Surrozen, Inc./DE operating lease, payments for fiscal 2024 was $2.67M, a 2.85% increase from fiscal 2023.
- Surrozen, Inc./DE operating lease, payments for fiscal 2023 was $2.60M, a 5.36% decline from fiscal 2022.
- Surrozen, Inc./DE operating lease, payments for fiscal 2022 was $2.74M, a 3.96% decline from fiscal 2021.
| Period end | Operating Lease, Payments 12 month |
|---|---|
| 2025-12-31 | $2.44M 10-K · filed 2026-03-23 |
| 2024-12-31 | $2.67M 10-K · filed 2026-03-23 |
| 2023-12-31 | $2.60M 10-K · filed 2025-03-31 |
| 2022-12-31 | $2.74M 10-K · filed 2024-04-10 |
| 2021-12-31 | $2.86M 10-K · filed 2023-03-31 |
| 2020-12-31 | $2.52M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |